Skip to content

A multicenter, double-blind, randomized controlled clinical study of jianpiyishenhuazhuo granules in the treatment of vascular dementia

A multicenter, double-blind, randomized controlled clinical study ofJianpi Yishen Huazhuo granules in the treatment of vascular dementia

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085454
Enrollment
Unknown
Registered
2024-06-07
Start date
2024-06-15
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vascular dementia

Interventions

test group:Jianpi Yishen Huazhuo granules
control groups:Jianpi Yishen Huazhuo granules placebo

Sponsors

Xiyuan Hospital, China Academy of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Meet the Western medical diagnostic criteria for vascular dementia. (2) Meet the Chinese medicine diagnostic criteria for vascular dementia. (3) Hachinski ischemia scale score = 7. (4) Clinical Dementia Rating Scale (CDR) dementia degree rating of mild and moderate dementia (CDR=1.0, 2.0). (5) 14 = MMSE score = 26. (6) Age 45-80 years old, gender is not limited. (7) Those who can cooperate in completing the test. (8) Voluntary subjects and their legal guardians sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Those who have been definitively diagnosed or suspected of having a combination of other types of dementia through existing history, scales, and imaging tests, such as Alzheimer's disease, dementia with Lewy bodies, frontotemporal lobe dementia, Parkinson's disease, mixed-type dementia, demyelinating diseases of the central nervous system, tumors, hydrocephalus, traumatic injuries, and infections of the central system; (2) Those who cannot complete the examination with severe neurological deficits, such as hemiplegia, various kinds of aphasia, and audio-visual disorders; (3) Abnormal laboratory parameters: Hb (hemoglobin) and Plt (platelet count) less than the lower limit; APTT (activated partial thromboplastin time) exceeding the normal value for more than 10 seconds, PT (plasminogen time) exceeding the normal value for more than 3 seconds; Cr (creatinine) exceeding 1.5 times the upper limit; ALT (alanine aminotransferase), AST (aspartate aminotransferase) or ALP (alkaline phosphate), Y-GL (alkaline phosphatase), and Y-phosphate. ALT (alanine aminotransferase), AST (aspartate aminotransferase) or ALP (alkaline phosphate), Y-GT (Y-glutamyltransferase) more than 2 times the upper limit of normal, and TBiL (total bilirubin) more than 1.5 times the upper limit of normal; (4) Severe mental illness (e.g., depression, schizophrenia) and epilepsy; (5) Alcohol and drug abusers; (6) The subject is allergic or hypersensitive to the test drug; (7) The following drugs are being used and cannot be stopped, such as Donepezil, Carboplatin, Staphylococcus aureus, Memantine, Nimodipine, etc.

Design outcomes

Primary

MeasureTime frame
VaDAS-Cog ;Chinese Medicine Symptom Score;

Countries

China

Contacts

Public ContactZhang Yunling

Xiyuan Hospital, China Academy of Traditional Chinese Medicine

yunlingzhang2004@126.com+86 139 1076 4257

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026